TEZSPIRE is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Amgen, Inc. The primary component is Tezepelumab.
| Product ID | 55513-112_25a4a901-927c-4f3a-a1c4-72826d46e946 |
| NDC | 55513-112 |
| Product Type | Human Prescription Drug |
| Proprietary Name | TEZSPIRE |
| Generic Name | Tezepelumab-ekko |
| Dosage Form | Injection, Solution |
| Route of Administration | SUBCUTANEOUS |
| Marketing Start Date | 2021-12-17 |
| Marketing Category | BLA / |
| Application Number | BLA761224 |
| Labeler Name | Amgen, Inc |
| Substance Name | TEZEPELUMAB |
| Active Ingredient Strength | 210 mg/1.9mL |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
| Marketing Start Date | 2021-12-17 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 55513-100 | TEZSPIRE | tezepelumab-ekko |
| 55513-112 | TEZSPIRE | tezepelumab-ekko |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() TEZSPIRE 97063714 not registered Live/Pending |
Amgen Inc. 2021-10-07 |
![]() TEZSPIRE 90873127 not registered Live/Pending |
Amgen Inc. 2021-08-09 |
![]() TEZSPIRE 90295725 not registered Live/Pending |
Amgen Inc. 2020-11-03 |